Found 1196 with Last Name = 'kormos' and Initial = 'bl' 
Affinity DataKi: 4.20nMAssay Description:Displacement of radiolabeled 4-(azetidin-1-yl)-3-[5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-1-(tritritiomethyl)pyrazolo[3,4-d]pyrimidine from PD...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0386nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0444nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0697nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0777nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0837nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0896nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0950nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.0998nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.101nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.102nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.106nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.110nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.123nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.125nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.130nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.132nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.136nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.142nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.144nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.147nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.147nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.163nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.166nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.170nMAssay Description:Inhibition of PDE5A1 (unknwon origin) using [3H]cGMP as substrate after 30 mins by SPAMore data for this Ligand-Target Pair
3D Structure (crystal)TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.171nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.174nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.174nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.175nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.177nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.178nMAssay Description:Inhibition of gamma secretase-mediated amyloid beta42 production in human H4 cells expressing human APP swedish mutantMore data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.182nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.193nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.194nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.196nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.205nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.211nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.219nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
Affinity DataIC50: 0.225nMAssay Description:Inhibition of gamma secretase-mediated amyloid beta42 production in human H4 cells expressing human APP swedish mutantMore data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.227nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.233nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.236nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: <0.240nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.255nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.257nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.265nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.265nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.270nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.275nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Pfizer
US Patent
Pfizer
US Patent
Affinity DataIC50: 0.277nMpH: 7.5Assay Description:The ability of a compound to inhibit PDE10 enzymatic activity can be demonstrated by any number of assays that are known in the art. The products of ...More data for this Ligand-Target Pair
